Regeneron Pharmaceuticals (REGN) Capital Leases (2009 - 2025)
Regeneron Pharmaceuticals (REGN) posted quarterly Capital Leases of $720.0 million for Q4 2025, little changed year-over-year from $720.0 million in Q4 2024, and little changed quarter-over-quarter from $720.0 million in Q3 2025.
Regeneron Pharmaceuticals (REGN) Capital Leases (2009 - 2025) Analysis & Trends
Regeneron Pharmaceuticals' Capital Leases history runs 16 years deep, the most recent figure standing at $720.0 million for Q4 2025.
- In Q4 2025, Capital Leases changed 0.0% year-over-year to $720.0 million; the TTM figure through Dec 2025 stood at $720.0 million (changed 0.0% YoY), while the FY2025 annual figure was $720.0 million, changed 0.0% from the prior year.
- Capital Leases for Q4 2025 stood at $720.0 million, roughly flat from $720.0 million in the prior quarter.
- The five-year high for Capital Leases was $720.0 million in Q1 2022, with the low at $720.0 million in Q1 2022.
- The 4-year median for Capital Leases is $720.0 million (2022), against an average of $720.0 million.
- Peak annual rise in Capital Leases reached 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
- Regeneron Pharmaceuticals' Capital Leases stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
- Business Quant data shows REGN's Capital Leases at $720.0 million in Q4 2025, $720.0 million in Q3 2025, and $720.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 720.00 Mn |
| Sep 30, 2025 | 720.00 Mn |
| Jun 30, 2025 | 720.00 Mn |
| Mar 31, 2025 | 720.00 Mn |
| Dec 31, 2024 | 720.00 Mn |
| Sep 30, 2024 | 720.00 Mn |
| Jun 30, 2024 | 720.00 Mn |
| Mar 31, 2024 | 720.00 Mn |
| Dec 31, 2023 | 720.00 Mn |
| Sep 30, 2023 | 720.00 Mn |
| Jun 30, 2023 | 720.00 Mn |
| Mar 31, 2023 | 720.00 Mn |
| Dec 31, 2022 | 720.00 Mn |
| Sep 30, 2022 | 720.00 Mn |
| Jun 30, 2022 | 720.00 Mn |
| Mar 31, 2022 | 720.00 Mn |
| Dec 31, 2020 | 717.20 Mn |
| Sep 30, 2020 | 716.50 Mn |
| Jun 30, 2020 | 715.90 Mn |
| Mar 31, 2020 | 715.20 Mn |